Show simple item record

dc.contributor.authorZhao, Liang
dc.contributor.authorCavallaro, Antonino S
dc.contributor.authorWibowo, David
dc.contributor.authorZhang, Bing
dc.contributor.authorZhang, Jun
dc.contributor.authorMitter, Neena
dc.contributor.authorYu, Chengzhong
dc.contributor.authorZhao, Chun-Xia
dc.contributor.authorMiddelberg, Anton PJ
dc.date.accessioned2018-03-08T03:14:56Z
dc.date.available2018-03-08T03:14:56Z
dc.date.issued2017
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2016.11.037
dc.identifier.urihttp://hdl.handle.net/10072/370761
dc.description.abstractAnaplasma marginale is a devastating tick-borne pathogen causing anaplasmosis in cattle and results in significant economic loss to the cattle industry worldwide. Currently, there is no widely accepted vaccine against A. marginale. New generation subunit vaccines against A. marginale, which are much safer, more efficient and cost-effective, are in great need. The A. marginale outer membrane protein VirB9-1 is a promising antigen for vaccination. We previously have shown that soluble recombinant VirB9-1 protein can be expressed and purified from Escherichia coli and induce a high level of humoral and cellular immunity in mice. In this study, we re-formulated the nanovaccines using the partially-purified VirB9-1 protein as the antigen and hollow nano-size silica vesicles (SV-100) as the adjuvant. We simplified the purification method to obtain the partially-purified antigen VirB9-1 with a six-fold higher yield. The new formulations using the partially-purified VirB9-1 protein achieved higher antibody and cell-mediated immune responses compared to the purified ones. This finding suggests that the partially-purified VirB9-1 protein performs better than the purified ones in the vaccination against A. marginale, and a certain level of contaminants in the protein antigen can be self-adjuvant and boost immunogenicity together with the nanoparticle adjuvant. This may lead to finding a “Goldilocks” level of contaminants. The new nanovaccine formulation using partially-purified antigens along with nanoparticle adjuvants offers an alternative strategy for making cheaper veterinary vaccines.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom77
dc.relation.ispartofpageto83
dc.relation.ispartofissue1
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume35
dc.subject.fieldofresearchGenetic Immunology
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchAgricultural and Veterinary Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchcode060406
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode07
dc.subject.fieldofresearchcode11
dc.titleA partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorWibowo, David


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record